PWM
ACAD icon

Parkworth Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Parkworth Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$22 Buy
+1
New +$19 ﹤0.01% 1336

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Parkworth Wealth Management's ACAD Position: Q2 2025 in Review

Parkworth Wealth Management opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2025: 1 share worth $22. The stake represents ﹤0.01% of the portfolio and ranks #1336 among its holdings.

310 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

  • Parkworth Wealth Management held 1 share of Acadia Pharmaceuticals worth $22 as of Q2 2025.
  • Acadia Pharmaceuticals was a new Parkworth Wealth Management position in Q2 2025.
  • Acadia Pharmaceuticals made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #1336 holding.
  • 310 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.